IL145922A0
(en)
|
1999-04-28 |
2002-07-25 |
Aventis Pharma Gmbh |
Di-aryl acid derivatives as ppar receptor ligands
|
TWI302149B
(en)
|
1999-09-22 |
2008-10-21 |
Bristol Myers Squibb Co |
Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
JP2004500389A
(ja)
*
|
2000-03-09 |
2004-01-08 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Pparメディエーターの治療での使用
|
JP2001261654A
(ja)
*
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
|
WO2002040458A1
(fr)
*
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Derives d'isoxazole
|
GB0029974D0
(en)
*
|
2000-12-08 |
2001-01-24 |
Glaxo Group Ltd |
Chemical compounds
|
US7238716B2
(en)
|
2000-12-28 |
2007-07-03 |
Takeda Pharmaceuticals Company Limited |
Alkanoic acid derivatives process for their production and use thereof
|
WO2002064632A2
(en)
*
|
2001-02-01 |
2002-08-22 |
Smithkline Beecham Corporation |
Crystallized ppar$g(a) ligand binding domain polypeptide and screening methods employing same
|
WO2002076959A1
(fr)
*
|
2001-03-23 |
2002-10-03 |
Takeda Chemical Industries, Ltd. |
Derive heterocyclique a cinq membres d'acide alcanoique
|
WO2002079162A1
(fr)
*
|
2001-03-28 |
2002-10-10 |
Eisai Co., Ltd. |
Acides carboxyliques
|
US7244861B2
(en)
|
2001-03-30 |
2007-07-17 |
Eisai Co., Ltd. |
Benzene compound and salt thereof
|
TWI311133B
(en)
*
|
2001-04-20 |
2009-06-21 |
Eisai R&D Man Co Ltd |
Carboxylic acid derivativeand the salt thereof
|
US20030092736A1
(en)
*
|
2001-05-30 |
2003-05-15 |
Cheng Peter T. |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
GB0113231D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Glaxo Group Ltd |
Chemical compounds
|
EP1394147A4
(en)
|
2001-06-04 |
2007-10-24 |
Eisai R&D Man Co Ltd |
CARBOXYLENE DERIVATIVE AND A SALT OR AN ESTER CONTAINING MEDICINE
|
DK1397130T3
(da)
|
2001-06-20 |
2007-11-12 |
Wyeth Corp |
Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
|
TWI224101B
(en)
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
US20110065129A1
(en)
|
2001-07-27 |
2011-03-17 |
Lowe Derek B |
Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
|
AR036237A1
(es)
|
2001-07-27 |
2004-08-25 |
Bayer Corp |
Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
|
ATE381542T1
(de)
*
|
2001-08-13 |
2008-01-15 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
JPWO2003016265A1
(ja)
|
2001-08-17 |
2004-12-02 |
エーザイ株式会社 |
環状化合物およびpparアゴニスト
|
PT1425014E
(pt)
*
|
2001-08-31 |
2007-03-30 |
Sanofi Aventis Deutschland |
Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
CA2487315A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Takeda Pharmaceutical Company Limited |
1,2-azole derivatives with hypoglycemic and hypolipidemic activity
|
JP2004277397A
(ja)
*
|
2002-05-24 |
2004-10-07 |
Takeda Chem Ind Ltd |
1,2−アゾール誘導体
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
GB0214149D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Chemical compounds
|
EP1517883B8
(en)
|
2002-06-20 |
2008-05-21 |
AstraZeneca AB |
Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
|
SE0201937D0
(sv)
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
Therapeutic agents
|
US7351858B2
(en)
|
2002-06-20 |
2008-04-01 |
Astrazeneca Ab |
Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
|
PL374860A1
(en)
|
2002-07-09 |
2005-11-14 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
JPWO2004007439A1
(ja)
*
|
2002-07-10 |
2005-11-10 |
住友製薬株式会社 |
ビアリール誘導体
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
OA12881A
(en)
|
2002-07-12 |
2006-09-15 |
Aventis Pharma Gmbh |
Heterocyclially substituted benzoylureas, method for their production and their use as medicaments.
|
EP1539137B1
(en)
*
|
2002-07-30 |
2010-05-26 |
Merck Sharp & Dohme Corp. |
Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
|
EP1541564A1
(en)
|
2002-09-10 |
2005-06-15 |
Takeda Pharmaceutical Company Limited |
Five-membered heterocyclic compounds
|
JP2004123732A
(ja)
*
|
2002-09-10 |
2004-04-22 |
Takeda Chem Ind Ltd |
5員複素環化合物
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
AU2003277576A1
(en)
|
2002-11-08 |
2004-06-07 |
Takeda Pharmaceutical Company Limited |
Receptor function controlling agent
|
AU2003290700A1
(en)
|
2002-11-22 |
2004-06-18 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
WO2004052854A2
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
UA80453C2
(en)
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
CA2509170A1
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
DK1569900T3
(da)
|
2002-12-10 |
2006-10-23 |
Wyeth Corp |
Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US6653334B1
(en)
*
|
2002-12-27 |
2003-11-25 |
Kowa Co., Ltd. |
Benzoxazole compound and pharmaceutical composition containing the same
|
JP2006516254A
(ja)
|
2003-01-06 |
2006-06-29 |
イーライ・リリー・アンド・カンパニー |
Pparモジュレータとしての縮合ヘテロ環誘導体
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7196114B2
(en)
|
2003-02-17 |
2007-03-27 |
Sanofi-Aventis Deutschland Gmbh |
Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308350B4
(de)
*
|
2003-02-27 |
2006-06-01 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 1,3-Cyclohexandiol-Derivaten
|
DE10308355A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308354A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308353A1
(de)
*
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10313228A1
(de)
*
|
2003-03-25 |
2004-10-21 |
Aventis Pharma Deutschland Gmbh |
Synthese von 2-Chlormethyl-6-methylbenzoesäureestern
|
US6989462B2
(en)
|
2003-03-25 |
2006-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of 2-chloromethyl-6-methylbenzoic ester
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US7244763B2
(en)
*
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
CA2527691C
(en)
|
2003-05-30 |
2013-01-22 |
Takeda Pharmaceutical Company Limited |
Condensed ring compound
|
UA88767C2
(uk)
|
2003-07-17 |
2009-11-25 |
Плексікон, Інк. |
Ppar активні сполуки
|
US7348338B2
(en)
|
2003-07-17 |
2008-03-25 |
Plexxikon, Inc. |
PPAR active compounds
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
WO2005016240A2
(en)
*
|
2003-08-01 |
2005-02-24 |
Nobex Corporation |
Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
|
DE10335450A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Ag |
Indolin-Sulfanilsäureamide
|
WO2005012221A1
(ja)
*
|
2003-08-04 |
2005-02-10 |
Ono Pharmaceutical Co., Ltd. |
ジフェニルエーテル化合物、その製造方法および用途
|
AU2004268839A1
(en)
|
2003-09-03 |
2005-03-10 |
Pfizer Inc. |
Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
|
EP1664002A1
(en)
*
|
2003-09-17 |
2006-06-07 |
Novartis AG |
Organic compounds
|
US7268159B2
(en)
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
US7351726B2
(en)
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
US7141592B2
(en)
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
US7332521B2
(en)
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
US7163954B2
(en)
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
US7446201B2
(en)
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
US7582773B2
(en)
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
US7411083B2
(en)
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
US7442805B2
(en)
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
BRPI0416106A
(pt)
|
2003-10-31 |
2007-01-02 |
Janssen Pharmaceutica Nv |
ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos
|
AU2004293013B2
(en)
|
2003-11-19 |
2011-04-28 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
US8008525B2
(en)
|
2003-11-26 |
2011-08-30 |
Takeda Pharmaceutical Company Limited |
Receptor function regulating agent
|
DE10360525B3
(de)
*
|
2003-12-22 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Herstellung von substituierten 2-(Phenoxymethyl)-benzoesäuren
|
US7238835B2
(en)
|
2003-12-22 |
2007-07-03 |
Sanofi-Aventis Deutschland Gmbh |
Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids
|
CA2551610A1
(en)
|
2003-12-25 |
2005-07-14 |
Takeda Pharmaceutical Company Limited |
3-(4-benzyloxyphenyl)propanoic acid derivatives
|
EP1698624B1
(en)
*
|
2003-12-26 |
2012-06-27 |
Takeda Pharmaceutical Company Limited |
Phenylpropanoic acid derivatives
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
BRPI0508098A
(pt)
|
2004-02-27 |
2007-07-17 |
Amgen Inc |
compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
US7166738B2
(en)
|
2004-04-23 |
2007-01-23 |
Roche Palo Alto Llc |
Non-nucleoside reverse transcriptase inhibitors
|
US7625949B2
(en)
|
2004-04-23 |
2009-12-01 |
Roche Palo Alto Llc |
Methods for treating retroviral infections
|
WO2006004030A1
(ja)
*
|
2004-07-02 |
2006-01-12 |
Sankyo Company, Limited |
組織因子産生抑制剤
|
BRPI0515015A
(pt)
|
2004-08-11 |
2008-07-01 |
Kyorin Seiyaku Kk |
derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
|
DE102004039509B4
(de)
*
|
2004-08-14 |
2006-09-21 |
Sanofi-Aventis Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
AU2005277138A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth Holdings Corporation |
Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (PAI-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
|
EP1814877B1
(en)
*
|
2004-10-18 |
2009-03-11 |
Merck & Co., Inc. |
Diphenyl substituted alkanes as flap inhibitors
|
CA2585623C
(en)
|
2004-10-27 |
2012-06-05 |
Daiichi Sankyo Company Limited |
Ortho-substituted benzene derivatives
|
EP1829863A4
(en)
*
|
2004-11-26 |
2009-04-22 |
Takeda Pharmaceutical |
ARYLALCANOIC ACID DERIVATIVE
|
JP2008521829A
(ja)
|
2004-11-30 |
2008-06-26 |
プレキシコン,インコーポレーテッド |
Ppar活性化合物
|
US20090036489A1
(en)
*
|
2005-03-22 |
2009-02-05 |
Masahiro Nomura |
Novel Cyclic Aminophenylalkanoic Acid Derivative
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
BRPI0614340A2
(pt)
|
2005-08-17 |
2011-04-12 |
Wyeth Corp |
indóis substituìdos e métodos de seu uso
|
TW200800872A
(en)
*
|
2005-09-07 |
2008-01-01 |
Plexxikon Inc |
PPAR active compounds
|
CN101272784A
(zh)
|
2005-09-29 |
2008-09-24 |
塞诺菲-安万特股份有限公司 |
苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
|
CA2625047A1
(en)
|
2005-10-19 |
2007-04-26 |
F. Hoffmann-La Roche Ag |
Phenyl-acetamide nnrt inhibitors
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
AU2007265966B2
(en)
|
2006-06-27 |
2012-05-17 |
Takeda Pharmaceutical Company Limited |
Fused cyclic compounds
|
JP2010504321A
(ja)
*
|
2006-09-21 |
2010-02-12 |
ピラマル・ライフ・サイエンシーズ・リミテッド |
インスリン抵抗性または高血糖に関連する代謝性障害の治療のためのピリジン誘導体
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
PL2125711T3
(pl)
*
|
2007-03-08 |
2014-05-30 |
Albireo Ab |
Pochodne kwasy 3-fenylopropionowego oraz ich zastosowanie w leczeniu nieswoistego zapalenia jelit
|
PE20090159A1
(es)
|
2007-03-08 |
2009-02-21 |
Plexxikon Inc |
COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
|
BRPI0701664A2
(pt)
*
|
2007-05-28 |
2009-01-13 |
Fundacao Universidade Fed De Sco Carlos |
4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN101381302B
(zh)
*
|
2007-09-07 |
2013-04-03 |
上海睿智化学研究有限公司 |
2-溴甲基-6-甲基苯甲酰氯/溴的制备方法
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
AU2008338963A1
(en)
*
|
2007-12-13 |
2009-06-25 |
Sri International |
PPAR-delta ligands and methods of their use
|
CA2707492A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Amgen Inc. |
Gamma secretase modulators
|
CA2713139C
(en)
|
2008-02-01 |
2013-04-23 |
Amira Pharmaceuticals, Inc. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
EP2257536A4
(en)
*
|
2008-02-14 |
2011-03-23 |
Amira Pharmaceuticals Inc |
CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
|
EP2245022A4
(en)
|
2008-02-25 |
2012-02-22 |
Panmira Pharmaceuticals Llc |
ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
|
US8426449B2
(en)
*
|
2008-04-02 |
2013-04-23 |
Panmira Pharmaceuticals, Llc |
Aminoalkylphenyl antagonists of prostaglandin D2 receptors
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
DE102008018675A1
(de)
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
|
BRPI0913930A2
(pt)
|
2008-07-03 |
2015-10-20 |
Amira Pharmaceuticals Inc |
antagonistas de receptores de prostaglandinas d2
|
EP2310372B1
(en)
|
2008-07-09 |
2012-05-23 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
WO2010009374A1
(en)
|
2008-07-18 |
2010-01-21 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
WO2010039977A2
(en)
|
2008-10-01 |
2010-04-08 |
Amira Pharmaceuticals, Inc. |
Heteroaryl antagonists of prostaglandin d2 receptors
|
WO2010042652A2
(en)
|
2008-10-08 |
2010-04-15 |
Amira Pharmaceuticals, Inc. |
Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
WO2010065883A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Method of treating an overweight or obese subject
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
US20100173313A1
(en)
*
|
2009-01-08 |
2010-07-08 |
Amira Pharmaceuticals, Inc. |
Biomarkers of inflammation
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
KR101457027B1
(ko)
|
2009-06-09 |
2014-10-31 |
캘리포니아 캐피탈 에쿼티, 엘엘씨 |
트리아진 유도체와 이들의 치료적 용도
|
CN102573484B
(zh)
|
2009-06-09 |
2015-07-01 |
加利福尼亚资本权益有限责任公司 |
苄基取代的三嗪衍生物及其治疗应用
|
KR20120018224A
(ko)
|
2009-06-09 |
2012-02-29 |
아브락시스 바이오사이언스, 엘엘씨 |
헷지호그 신호전달 억제제로서의 이소퀴놀린, 퀴놀린 및 퀴나졸린 유도체
|
CN102596902A
(zh)
*
|
2009-08-05 |
2012-07-18 |
潘米拉制药公司 |
Dp2拮抗剂及其用途
|
DK2470552T3
(en)
|
2009-08-26 |
2014-02-17 |
Sanofi Sa |
NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
|
MX2012003400A
(es)
|
2009-10-02 |
2012-04-10 |
Sanofi Sa |
Uso de compuestos con actividad inhibidora de sglt - 1/sglt - 2 para producir medicamentos para el tratamiento de enfermedades oseas.
|
KR20120083905A
(ko)
*
|
2009-10-09 |
2012-07-26 |
자프겐 코포레이션 |
비만의 치료에 사용하기 위한 설폰 화합물
|
DE102009046115A1
(de)
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 3-Phenylpropansäuren und ihre Verwendung
|
JP2013516475A
(ja)
|
2010-01-06 |
2013-05-13 |
アミラ ファーマシューティカルズ,インク. |
Dp2アンタゴニストおよびその使用
|
WO2011085198A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
|
BR112012016793A2
(pt)
|
2010-01-08 |
2018-07-31 |
Zafgen Corp |
compostos tipo fumagilol e métodos de fazer e usar os mesmos
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011127304A2
(en)
|
2010-04-07 |
2011-10-13 |
Zafgen Corporation |
Methods of treating an overweight subject
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
EP2590951B1
(en)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
EP2593433B1
(en)
|
2010-07-12 |
2014-11-26 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
WO2012007868A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
CA2804877A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
US9102621B2
(en)
|
2010-07-12 |
2015-08-11 |
Pfizer Limited |
Acyl sulfonamide compounds
|
US9266896B2
(en)
|
2010-07-22 |
2016-02-23 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|
UA111479C2
(uk)
|
2010-11-09 |
2016-05-10 |
Зафджен, Інк. |
Кристалічні форми інгібітору metap-2 та способи їх отримання і застосування
|
CA2819251A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
|
AU2011340721A1
(en)
|
2010-12-07 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
|
BR112013016033A2
(pt)
|
2010-12-23 |
2018-06-05 |
Pfizer |
moduladores do receptor de glucagon
|
WO2012103333A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen Corporation |
Tetrazole compounds and methods of making and using same
|
ES2597972T3
(es)
|
2011-02-08 |
2017-01-24 |
Pfizer Inc |
Modulador del receptor de glucagón
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
BR112013023056A2
(pt)
|
2011-03-08 |
2018-10-09 |
Zafgen Inc |
derivados de oxaespiro [2,5] octano e análogos
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
BR112013028665A2
(pt)
|
2011-05-06 |
2016-09-06 |
Zafgen Inc |
compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
|
KR20140040739A
(ko)
|
2011-05-06 |
2014-04-03 |
자프겐 인크. |
삼환식 피라졸 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
|
KR101979039B1
(ko)
|
2011-05-06 |
2019-05-15 |
자프겐 인크. |
부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
|
ES2550345T3
(es)
|
2011-07-22 |
2015-11-06 |
Pfizer Inc. |
Moduladores del receptor de quinolinilglucagón
|
SG2014011555A
(en)
|
2011-08-15 |
2014-08-28 |
Intermune Inc |
Lysophosphatidic acid receptor antagonists
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2763671A2
(en)
|
2011-10-03 |
2014-08-13 |
Zafgen, Inc. |
Methods of treating age related disorders
|
JP6035347B2
(ja)
|
2012-01-18 |
2016-11-30 |
ザフゲン,インコーポレイテッド |
三環式スルホンアミド化合物ならびにその作製および使用方法
|
US9440943B2
(en)
|
2012-01-18 |
2016-09-13 |
Zafgen, Inc. |
Tricyclic sulfone compounds and methods of making and using same
|
JP2015516425A
(ja)
|
2012-05-07 |
2015-06-11 |
ザフゲン,インコーポレイテッド |
6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールのシュウ酸塩の多形塩ならびにその製造および使用方法
|
JP2015516426A
(ja)
|
2012-05-08 |
2015-06-11 |
ザフゲン,インコーポレイテッド |
MetAP2阻害剤による視床下部性肥満症の治療
|
KR20150016534A
(ko)
|
2012-05-09 |
2015-02-12 |
자프겐 인크. |
푸마지롤형 화합물 및 이의 제조 및 사용 방법
|
DE102012208530A1
(de)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituierte Piperidinoacetamide und ihre Verwendung
|
BR112015010225A2
(pt)
|
2012-11-05 |
2017-07-11 |
Zafgen Inc |
compostos tricíclicos e seus métodos de produção e utilização
|
CN104918615B
(zh)
|
2012-11-05 |
2018-10-12 |
扎夫根股份有限公司 |
治疗肝病的方法
|
EP2925737B1
(en)
|
2012-11-05 |
2017-06-14 |
Zafgen, Inc. |
Tricyclic compounds for use in the treatment and/or control of obesity
|
BR112015023390A2
(pt)
|
2013-03-14 |
2017-07-18 |
Zafgen Inc |
métodos para tratar de doença renal e outros distúrbios
|
MX2015011445A
(es)
|
2013-03-15 |
2016-04-20 |
Global Blood Therapeutics Inc |
Compuestos y usos de estos para la modulacion de la hemoglobina.
|
WO2015057659A1
(en)
|
2013-10-14 |
2015-04-23 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
AU2014334551B2
(en)
|
2013-10-14 |
2018-05-10 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
EA202092627A1
(ru)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
JP6699011B2
(ja)
*
|
2014-07-04 |
2020-05-27 |
国立大学法人 東京大学 |
脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体
|
EP2982667A1
(en)
*
|
2014-08-04 |
2016-02-10 |
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. |
Competitive PPAR-gamma antagonists
|
MX2017004652A
(es)
|
2014-10-10 |
2017-06-19 |
Pulmocide Ltd |
Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.
|
JP6694886B2
(ja)
|
2014-12-18 |
2020-05-20 |
プルモシデ リミテド |
4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
|
CA2970987A1
(en)
|
2014-12-18 |
2016-06-23 |
Bayer Pharma Aktiengesellschaft |
Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
|
CN106432255A
(zh)
|
2015-08-11 |
2017-02-22 |
扎夫根公司 |
烟曲霉素醇螺环化合物和制备和使用其的方法
|
AR105671A1
(es)
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|
JOP20200001A1
(ar)
|
2017-07-11 |
2022-10-30 |
Vertex Pharma |
كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
|
US11612580B2
(en)
|
2017-10-16 |
2023-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions for inhibiting 3′ repair exonuclease 2 and methods of screening for such compositions
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
CR20220316A
(es)
|
2019-12-06 |
2022-10-07 |
Vertex Pharma |
Tetrahidrofuranos sustituidos como moduladores de canales de sodio
|
US11827627B2
(en)
|
2021-06-04 |
2023-11-28 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
|
WO2024039864A1
(en)
*
|
2022-08-19 |
2024-02-22 |
Purdue Research Foundation |
Protein:protein interaction inhibitors
|